• Insulet narrowed FY 2026 total revenue growth guidance to 20%-22% on a constant-currency basis, down from 21%-23%.
• Total Omnipod growth outlook cut to 21%-23% from 22%-24%; U.S. Omnipod trimmed to 17%-19% from 20%-22%.
• International Omnipod forecast raised to 30%-32% from 26%-28% on constant currency.
• Q3 2026 total revenue growth expected at 17.5%-19.5%.
• Guidance assumes continued Omnipod 5 adoption; U.S. expectations reflect lower utilization and higher attrition than previously expected, especially in T2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.